Síntese, avaliação biológica e docking de novos derivados 2,3-substituídos-1,4-naftoquinônicos contendo nitrogênio, oxigênio e enxofre com atividade anticâncer

• Ano de defesa: 2013
• Autor(a) principal: Delarmelina, Maicon
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; BR; Mestrado em Química; Centro de Ciências Exatas; UFES; Programa de Pós-Graduação em Química
• Palavras-chave em Português: Docking; Naftoquinona; Agentes antineoplásicos; Enzimas; Topoisomerase; Química; 54
• Link de acesso: http://repositorio.ufes.br/handle/10/4694

Cancer is one of the most feared disease in society, which have become a stigma of death and pain. Statistically, a survey conducted by the World Health Organization (WHO), cancer is the second cause of death in the world with 13%, killing about 6.0 million people per year. It is believed that in 2015 cancer will be responsible for over 9 million deaths worldwide. The advances achieved in recent decades in cancer chemotherapy research have greatly facilitated the implementation of other types of cancer treatment and allowed a greater number of cures. However, many cancers are intrinsically resistant to chemotherapy, while others respond to initial treatment, but it acquires drug resistance. The multiple drug resistance (MDR), the most severe case, occurs when in vitro and in vivo cell cultures show simultaneous resistance to different drugs. Therefore, despite the large number of compounds that make up the arsenal of anti-cancer chemotherapy, the resistance problem requires a constant search for effective new drugs in fighting cancer, a disease that affects millions of people. In pharmacological studies with various quinones was evidenced that these substances show different pharmacodynamic activities, among them, cytotoxic properties and inhibiting cellular systems repairers, processes in which they act in different ways. As an example, there is oxidative stress that cause deleterious by inducing formation of endogenous bioactive oxygen species derived (ROS). Another remarkable activity of these substances, recently discovered, is the inhibition of the enzyme topoisomerase II, an action that triggers the onset of cellular apoptosis. In this work were synthesized eleven 1,4-naphthoquinone derivatives containing functional groups, nitrogen and sulfur in positions 2 and/or 3 naphthoquinone core in yields ranging 52-89%. Subsequently these compounds had their cytotoxicity evaluated in strains of human lung cancer (H460), triple-negative breast (MDA-MB- 231) and ovarian (A2780). Compounds 25f and 44, 44 and 25c, and 25g and 44 showed a significant anticancer in vitro activity for the strains of lung cancer H460, triple-negative breast MDA-MB-231 and ovarian A2780, respectively, showing a great potential as lead compounds for the development of new anticancer agents. Docking studies of the four most active compounds with therapeutic targets PI3K and topoisomerase II were performed. Those studies have shown that a 16 possible therapeutic target of synthesized compounds is topoisomerase II enzyme because of the observed enzyme/binder complex stabilizing interactions.